| 货号 | 4735S |
| 反应种属 | Human/Mouse/Rat |
| 来源宿主 | Rabbit |
| 应用 | W/IHC-P |
| 使用方法 | WB(1:1000) IHC-P (1:25) |
| 供应商 | CST |
| 背景 | RNA polymerase II is a complex of 12 proteins that participates in transcription, mRNA processing, and transcription-coupled DNA repair (1,2). The largest subunit, Rpb1, contains a unique heptapeptide: Tyr1, Ser2, Pro3, Thr4, Ser5, Pro6, Ser7, which is repeated up to 52 times in the carboxy-terminal domain (CTD) of Rpb1 (3). This CTD is phosphorylated by cyclin-dependent kinases (CDKs), p44/42 MAPK, DNA-PKcs, and c-Abl (4). DNA damage caused by UV-light, hydrogen peroxide, or cisplatin results in ubiquitination and proteasomal degradation of Rpb1 (1,3). The kinase inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole prevents ubiquitination of Rpb1, suggesting that CTD phosphorylation is required for proteolysis (5).RNA 聚合酶 II是由12种蛋白组成的复合体，参与转录、mRNA处理和转录偶联DNA修复(1,2)。最大的亚基Rpb1包含一个独特的七肽：Tyr1, Ser2, Pro3, Thr4, Ser5, Pro6, Ser7，在Rpb1的羧基末端结构域(CTD)发生高达52次的重复(3)。该结构域能够被周期蛋白依赖性激酶 (CDKs)，p44/42 MAPK，DNA-PKcs和c-Abl 磷酸化(4)。紫外线、过氧化氢和顺铂引起的DNA损伤能够导致Rpb1的泛素化和蛋白酶体降解(1,3)。激酶抑制剂5,6-二氯-1-β-D-呋喃核糖基苯并咪唑能够阻止Rpb1的泛素化表明CTD磷酸化为蛋白酶解所必需(5)。 |
| 存放说明 | -20C |
| 计算分子量 | 250 |
Immunohistochemical analysis of paraffin-embedded human lung carcinoma, showing nuclear localization, using Phospho-Rpb1 CTD (Ser2/5) Antibody.免疫组织化学方法检测石蜡包埋人类肺癌组织，显示核定位，使用的抗体为 Phospho-Rpb1 CTD (Ser2/5) Antibody。 | |
Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using Phospho-Rpb1 CTD (Ser2/5) Antibody in the presence of control peptide (left) or antigen-specific peptide (right).免疫组织化学方法检测石蜡包埋人类结肠癌组织，使用的抗体为 Phospho-Rpb1 CTD (Ser2/5) Antibody，左图为与对照多肽共孵育，右图为抗原特异性多肽共孵育。 | |
Immunohistochemical analysis of paraffin-embedded human renal cell carcinoma, untreated (left) or λ phosphatase-treated (right), using Phospho-Rpb1 CTD (Ser2/5) Antibody.免疫组织化学方法检测石蜡包埋人类肾细胞癌组织，分为非处理组（左图）或λ磷酸酶处理组（右图），使用的抗体为 Phospho-Rpb1 CTD (Ser2/5) Antibody。 | |
Western blot analysis of extracts from MCF-7 cells, untreated or treated with doxorubicin (0.5 μM, 36 h), doxorubicin followed by λ Phosphatase NEB#P0753 (10,000 Units/ml, 1 h), nocodazole (50 ng/ml, 36 h) or nocodazole followed by λ Phosphatase, using Phospho-Rpb1 CTD (Ser2/5) Antibody (upper) or p53 Antibody #9282 (lower).Western blot方法检测MCF-7细胞，分为非处理组，阿霉素(0.5 μM)处理36小时组，λ磷酸酶(10,000 Units/ml，NEB#P0753)处理1小时后阿霉素处理组，诺考达唑(50 ng/ml)处理36小时组或λ磷酸酶处理后诺考达唑处理组，使用的抗体为Phospho-Rpb1 CTD (Ser2/5) Antibody (上图) 或 p53 Antibody #9282 (下图)。 |
